title: Surgical treatment of age-related macular degeneration: will there be a role in the future?
abstract: Surgical treatment has been shown to be able to improve vision that is lost as a result of age-related macular degeneration. Surgery is complex, such that improvement has always to be weighed against risk of complications. The availability of Ranibizumab and Bevacizumab is set to dramatically alter our management options. Surgical treatment will have a limited role to play in the next few years.
authors.affiliation: University of Hong Kong, Li Ka Shing Faculty of Medicine, Pok Fu Lam, Hong Kong, China. saihungdavid@mac.com
authors.forename: David
authors.initials: D
authors.lastname: Wong
authors.forename: Jon M
authors.initials: JM
authors.lastname: Durnian
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D017281:Cost of Illness; D006801:Humans; D008268:Macular Degeneration / Q000191:economics / Q000209:etiology / Q000601:surgery*; D013508:Ophthalmologic Surgical Procedures / Q000639:trends*; D000069579:Ranibizumab; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D000069579:Ranibizumab